Bone Biologics Corp (NASDAQ:BBLG) shares traded 43.62% higher at $0.78 on Wall Street last session.
In accordance with the data, 1 analysts cover Bone Biologics Corp (NASDAQ:BBLG). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $7.50 and a low of $7.50, we find $7.50. Given the previous closing price of $0.54, this indicates a potential upside of 1288.89 percent. BBLG stock price is now 27.74% away from the 50-day moving average and -80.19% away from the 200-day moving average. The market capitalization of the company currently stands at $2.44M.
It has been rated a hold by 0 analysts and a buy by 1. Brokers who have rated the stock have averaged $7.50 as their price target over the next twelve months.
In other news, Walsh Deina H, Chief Financial Officer bought 8,000 shares of the company’s stock on Sep 13. The stock was bought for $5,120 at an average price of $0.64. Upon completion of the transaction, the Chief Financial Officer now directly owns 15,000 shares in the company, valued at $11700.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 11, Chief Executive Officer Frelick Jeff bought 9,500 shares of the business’s stock. A total of $6,530 was incurred on buying the stock at an average price of $0.69. This leaves the insider owning 17,204 shares of the company worth $13419.12. Insiders disposed of 500,137 shares of company stock worth roughly $0.39 million over the past 1 year. A total of 12.54% of the company’s stock is owned by insiders.
Bone Biologics Corp (NASDAQ: BBLG) opened at $0.8100 on Thursday. During the past 12 months, Bone Biologics Corp has had a low of $0.47 and a high of $13.20. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.69, and a quick ratio of 1.69. The fifty day moving average price for BBLG is $0.6106 and a two-hundred day moving average price translates $3.9389 for the stock.
The latest earnings results from Bone Biologics Corp (NASDAQ: BBLG) was released for Sep, 2023.
Bone Biologics Corp(BBLG) Company Profile
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company’s NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L2-S1. The company’s platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.